GET DAILY SIGNALSCVS Health (CVS): Q1 2026 Earnings Preview and What Investors Should Watch
Key Takeaways
- Analysts expect Q1 2026 revenue of approximately $94.98 billion, implying slight growth from $94.6 billion in Q1 2025.
- Consensus adjusted EPS estimate stands at $2.21, a 1.8% decline from $2.25 reported last year.
- CVS Health reaffirmed FY2026 adjusted EPS guidance of $7.00–$7.20, signaling confidence in full-year performance.
- Health Care Benefits segment trends, including Medicare Advantage enrollment and medical costs, are key focuses.
- The company uses a calendar fiscal year, with Q1 covering January–March 2026.
- Stock has risen about 3–5% year-to-date in 2026 amid broader healthcare sector dynamics.
Earnings Context and Why It Matters
As CVS Health's Q1 earnings approach before the market opens on May 6, 2026, I'm paying close attention to how the company is managing its integrated model across retail pharmacy, pharmacy benefits management (PBM), and health insurance through Aetna. With medical costs on the rise and increased regulatory focus on PBM practices and Medicare Advantage (MA) plans, investors like us are looking for evidence of stable margins and membership growth. This report comes after a robust Q4 2025, where full-year revenue reached a record $402.1 billion, even as adjusted EPS came in at $6.75. Shares have climbed modestly year-to-date, and from what I see, the results could shape views on whether CVS can handle ongoing healthcare cost challenges while advancing its turnaround efforts.
Earnings Expectations
Wall Street's consensus points to Q1 revenue of $94.98 billion, according to MarketBeat, marking roughly 0.4% growth from $94.6 billion in the year-ago quarter. This reflects steady pharmacy sales and expansion in Health Services. The adjusted EPS estimate sits at $2.21, a slight dip from $2.25 last year, with Zacks showing a comparable revenue view of $94.37 billion and noting possible pressure from the Health Care Benefits medical loss ratio (MLR, the percentage of premiums spent on care). CVS has surpassed EPS estimates in the past four quarters by an average of 20.6%, frequently helped by favorable prior period development in insurance reserves. One thing that stands out for me is keeping an eye on Pharmacy & Consumer Wellness same-store sales, PBM script trends, and updates on MA membership. The company's FY2026 adjusted EPS guidance of $7.00–$7.20 suggests consistent delivery, backed by at least $9 billion in cash flow from operations.
Market Reaction and Investor Sentiment
Sentiment heading into Q1 feels cautiously optimistic, with CVS shares up about 3.41% year-to-date as of early May 2026, holding up better than some peers thanks to steady guidance. Looking at history, post-earnings reactions have been volatile: across 19 events over five years, positive 1-day returns happened 47% of the time, with media strong performance on beats and losses of 3.1% on misses. In my view, risks like a higher-than-expected MLR from MA utilization or PBM pricing pressures could weigh on the stock, while beats on guidance might drive gains.
Why I Rely on Tickeron’s AI Screener
In my own research process, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs by filtering on technical patterns, fundamentals, trends, volatility, and AI signals. It lets me scan thousands of stocks and ETFs with customizable criteria like industry, market cap, technical indicators, price patterns, and performance metrics—far more efficiently than manual methods. I've found it particularly useful for spotting trade ideas, trending stocks, breakout candidates, and opportunities in sectors like healthcare. If you're analyzing names like CVS, it's worth checking out to sharpen your edge.
Forward Outlook and Key Factors to Monitor
After Q1, the focus shifts to executing on the reaffirmed FY2026 adjusted EPS guidance of $7.00–$7.20, an increase from 2025's $6.75. This underscores confidence in CVS's vertical integration, though I'm watching Health Care Benefits trends especially closely.
Key areas include Medicare Advantage enrollment, influenced by regulatory changes and star ratings that affect reimbursements. Medical cost trends and MLR remain critical; Q4 2025 highlighted pressures from Inflation Reduction Act changes in Medicare Part D (prescription drug coverage).
In Pharmacy Services, script volume growth and generic dispensing rates will be telling. Retail pharmacy continues to face same-store sales challenges from front-store traffic and drug mix.
Broader elements to track are PBM rebate negotiations, potential M&A activity, and cash flow for dividends or buybacks. Cost controls and digital health initiatives could bolster margins, even as the industry grapples with drug pricing reforms. These dynamics will determine if CVS achieves mid-teens adjusted EPS growth through 2028.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CVS in upward trend: price rose above 50-day moving average on October 15, 2026
CVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on CVS as a result. In 60 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on October 06, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 23 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CVS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.500) is slightly lower than the industry average of (3.500). P/E Ratio (24.469) is within average values for comparable stocks, (127.108). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.028) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement